These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 30362607)

  • 1. Combination therapy of sorafenib with mesenchymal stem cells as a novel cancer treatment regimen in xenograft models of hepatocellular carcinoma.
    Seyhoun I; Hajighasemlou S; Muhammadnejad S; Ai J; Nikbakht M; Alizadeh AA; Hosseinzadeh F; Mirmoghtadaei M; Seyhoun SM; Verdi J
    J Cell Physiol; 2019 Jun; 234(6):9495-9503. PubMed ID: 30362607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and Validation of Hepatocellular Carcinoma (HCC) Xenograft tumor as a Suitable Liver Cancer Model for Preclinical Mesenchymal Stem Cell Studies.
    Hajighasemlou S; Pakzad S; Ai J; Muhammadnejad S; Mirmoghtadaei M; Hosseinzadeh F; Gharibzadeh S; Kamali A; Ahmadi A; Verdi J
    Asian Pac J Cancer Prev; 2018 Jun; 19(6):1627-1631. PubMed ID: 29936790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-inflammatory effect of mesenchymal stem cells on hepatocellular carcinoma in the xenograft mice model.
    Hajighasemlou S; Nikbakht M; Pakzad S; Azadbakht A; Muhammadnejad S; Mirmoghtadaei M; Gharibzadeh S; Seyhoun I; Verdi J
    Vet Med Sci; 2022 Sep; 8(5):2086-2091. PubMed ID: 35838746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
    Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
    J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
    J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells.
    Seyhoun I; Hajighasemlou S; Ai J; Hosseinzadeh F; Mirmoghtadaei M; Seyhoun SM; Parseh B; Abdolahi S; Ghazvinian Z; Shadnoush M; Verdi J
    Asian Pac J Cancer Prev; 2019 Jan; 20(1):263-267. PubMed ID: 30678447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
    Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
    Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
    Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.
    Gan G; Shi Z; Shangguan C; Zhang J; Yuan Y; Chen L; Liu W; Li B; Meng S; Xiong W; Mi J
    Theranostics; 2021; 11(12):6006-6018. PubMed ID: 33897895
    [No Abstract]   [Full Text] [Related]  

  • 13. Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study.
    Ma D; Wang J; Liu L; Chen M; Wang Z
    BMC Cancer; 2020 Sep; 20(1):936. PubMed ID: 32993568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of the microtubule inhibitor MBRI-001 against human hepatocellular carcinoma as monotherapy or in combination with sorafenib.
    Deng M; Li L; Zhao J; Yuan S; Li W
    Cancer Chemother Pharmacol; 2018 May; 81(5):853-862. PubMed ID: 29532153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ropivacaine synergizes with sorafenib to induce apoptosis of hepatocellular carcinoma cells via the IL-6/STAT3 pathway.
    Wang W; Lin H; Liu D; Wang T; Zhu Z; Yu P; Zhang J
    Cancer Sci; 2024 Sep; 115(9):2923-2930. PubMed ID: 39014520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma.
    Zhang QY; Ding W; Mo JS; Ou-Yang SM; Lin ZY; Peng KR; Liu GP; Lu JJ; Yue PB; Lei JP; Wang YD; Zhang XL
    Acta Pharmacol Sin; 2024 Aug; 45(8):1701-1714. PubMed ID: 38609562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
    Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.
    Wild AT; Gandhi N; Chettiar ST; Aziz K; Gajula RP; Williams RD; Kumar R; Taparra K; Zeng J; Cades JA; Velarde E; Menon S; Geschwind JF; Cosgrove D; Pawlik TM; Maitra A; Wong J; Hales RK; Torbenson MS; Herman JM; Tran PT
    PLoS One; 2013; 8(6):e65726. PubMed ID: 23762417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma.
    Wang P; Jiang Z; Liu X; Yu K; Wang C; Li H; Zhong L
    Cancer Med; 2020 Oct; 9(19):6972-6983. PubMed ID: 32779397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.